Riccardo Lowi analyst at Capital Network talks through Evgen Pharma that has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug.
Important – Please read this information: This video has been commissioned by Evgen Pharma and prepared and issued by Capital Network for publication globally. All information used in the publication of this video has been compiled from publicly available sources that are believed to be reliable, however, we do not guarantee the accuracy of this video. Opinions contained in this video represent those of the research department of Capital Network at the time of publication. The securities described in the video may not be eligible for sale in all jurisdictions or to certain categories of investors. Capital Network does not offer or provide personalised advice. We publish information about companies in which we believe our viewers may be interested in and this information reflects our opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Capital Network’s solicitation to effect, or attempt to effect, any transaction in a security. This document is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this video. This video is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this video. Capital Network has a restrictive policy relating to personal dealing. Capital Network does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this video. However, the respective directors, officers, employees and contractors of Capital Network may have a position in any or related securities mentioned in this video. Capital Network or its affiliates may perform services or solicit business from any of the companies mentioned in this video. The value of securities mentioned in this video can fall as well as rise and could be subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this video. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this video contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. The content of this video is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this video is not a “personalised service”. It should not be relied upon in making an investment decision. To the maximum extent permitted by law, Capital Network, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this video and do not guarantee the returns on investments in the products discussed in this publication.